Last updated on December 2019

Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301


Brief description of study

The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting.

Detailed Study Description

NODE-301 is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a nasal spray of etripamil, a new calcium channel blocker, in patients who experience an episode of paroxysmal ventricular tachycardia (PSVT).

The study will comprise of 2 parts, Part 1 and Part 2. Part 1 will consist of patients that will be dosed with the double-blind study drug or have discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode. The data from patients in Part 1 will be cleaned and locked, on a per-patient basis, and will be included in pivotal analyses. Pivotal analyses will include safety; and primary, secondary, and exploratory efficacy analyses for Part 1 only. Patients in Part 1 will be unblinded after data is locked.

Part 2 will consist of patients that will not be included in Part 1, i.e., Part 2 will consist of patients who were not dosed with the double-blind study drug or have not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode. The data from patients in Part 2 will be combined with that from Part 1 and will be included in exploratory analyses. Exploratory analyses will include safety; and primary, secondary, and exploratory efficacy analyses for Parts 1 and 2 combined. Patients in Part 2 will be unblinded at the end of the study. Part 2 will end when one of the following criteria is met:

  • 75% of patients in Part 2 have completed the study (Final Study Visit), or
  • Approximately 9 months after the date of the adjudication of the 150th positively adjudicated PSVT episode.

Based on the results of the pivotal analyses from Part 1, the planned statistical analysis and conduct of Part 2 may be amended. However, in no case will the Part 2 dataset be integrated with the Part 1 pivotal dataset for primary efficacy or primary safety analyses.

The study will include a Screening Visit, a Test Dose Randomization Visit, Follow-up Visits, a Treatment Period, and a Final Study Visit.

Clinical Study Identifier: NCT03464019

Find a site near you

Start Over

Baylor College of Medicine

Houston, TX United States
  Connect »

Los Alamitos Cardiovascular

Los Alamitos, CA United States
  Connect »

Weill Cornell Medical Center

New York, NY United States
  Connect »

New Mexico Heart Institute

Albuquerque, NM United States
  Connect »

Piedmont Heart Institute

Atlanta, GA United States
  Connect »

Trinity Medical WNY, PC

Buffalo, NY United States
  Connect »

Sima Research Clinic

Miami, FL United States
  Connect »

Mercy General Hospital

Sacramento, CA United States
  Connect »

Mayo Clinic - Jacksonville

Jacksonville, FL United States
  Connect »

Arkansas Cardiology

Little Rock, AR United States
  Connect »

ClinScale Management, LLC

Visalia, CA United States
  Connect »

Baptist Health Ambulatory Services

Jacksonville, FL United States
  Connect »

Iowa Heart Center

West Des Moines, IA United States
  Connect »

Ascension Providence Hospital

Southfield, MI United States
  Connect »

The Valley Hospital

Ridgewood, NJ United States
  Connect »

Peak Cardiology

Apex, NC United States
  Connect »

ProMedica Toledo Hospital

Toledo, OH United States
  Connect »

AIM Trials

Fort Worth, TX United States
  Connect »

Centra Cardiovascular Group

Lynchburg, VA United States
  Connect »

Manna Research

Stoney Creek, ON Canada
  Connect »